Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 9/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | VNN1 | O95497 | 6/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16738674 | 0.87 | DGAT2 (0.57) | DGAT2LMNAHTTSMN1; SMN2KDM4E | |
| SCHEMBL20239203 | 0.86 | DGAT2 (0.59) | DGAT2LMNASMN1; SMN2KDM4EVNN1 | |
| SCHEMBL20239333 | 0.86 | DGAT2 (0.56) | DGAT2LMNASMN1; SMN2P2RX3KDM4E | |
| SCHEMBL20239227 | 0.85 | DGAT2 (0.56) | DGAT2LMNASMN1; SMN2P2RX3KDM4E | |
| SCHEMBL20239171 | 0.85 | DGAT2 (0.56) | DGAT2LMNAHTTSMN1; SMN2KDM4E | |
| SCHEMBL20239176 | 0.84 | DGAT2 (0.55) | DGAT2LMNAHTTSMN1; SMN2KDM4E | |
| SCHEMBL20239169 | 0.84 | DGAT2 (0.54) | DGAT2LMNASMN1; SMN2KDM4EVNN1 | |
| SCHEMBL20239272 | 0.83 | DGAT2 (0.55) | DGAT2SMN1; SMN2KDM4EVNN1 | |
| SCHEMBL18249759 | 0.80 | DGAT2 (0.49) | DGAT2LMNAHTTSMN1; SMN2KDM4E | |
| SCHEMBL20239261 | 0.79 | DGAT2 (0.51) | DGAT2LMNAHTTSMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107635975-B | DGAT2 inhibitors | 伊莱利利公司 | 2020-07-24 | — | — | CN | disclosed |
| EP-3298001-B1 | DGAT2 INHIBITORS | LILLY CO ELI (US) | 2020-05-13 | — | — | EP | disclosed |
| US-10053429-B2 | DGAT2 inhibitors | ELI LILLY AND COMPANY (US) | 2018-08-21 | — | — | US | disclosed |
| US-20180162825-A1 | NOVEL DGAT2 INHIBITORS | ELI LILY AND COMPANY (US) | 2018-06-14 | — | — | US | disclosed |
| US-20180162825-A1 | NOVEL DGAT2 INHIBITORS | ELI LILY AND COMPANY (US) | 2018-06-14 | — | — | US | disclosed |
| EP-3298001-A1 | NOVEL DGAT2 INHIBITORS | Eli Lilly and Company (US) | 2018-03-28 | — | — | EP | disclosed |
| WO-2016187384-A1 | NOVEL DGAT2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2016-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162825-A1 | NOVEL DGAT2 INHIBITORS | DGAT2, DGAT1, LCAT | DGAT2 1/4885LMNA 2022/4885HTT 1239/4885 |
| US-10053429-B2 | DGAT2 inhibitors | DGAT2, DGAT1, LCAT | DGAT2 1/4885LMNA 1722/4885HTT 1291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.